Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on May 12, 2025

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and …

Vireo Growth Inc. Announces Closing of WholesomeCo Cannabis & Arches Merger Transactions
– Acquisitions strengthen profitability and competitive position with proprietary technology platform – – Missouri and Nevada transactions remain on track to close during the second quarter of 2025 – MINNEAPOLIS, May 12, 2025 (GLOBE NEWSWIRE) -- Vireo …

Cellectis Reports Financial Results for the First Quarter 2025
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 …

Editas Medicine Announces First Quarter 2025 Results and Business Updates
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo …

Global Pathology Imaging Systems Market Poised for Robust Growth, Set to Reach USD 2,603.74 Million by 2032
Advancements in Pathology Imaging Systems: A Growing Market Shaping the Future of Diagnostics and Healthcare. NEWARK, DE, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- The global pathology imaging systems market is projected to witness impressive …

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b …

Maravai Lifesciences Reports First Quarter 2025 Financial Results
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first …

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025 Cash, …

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise …

LifeMD to Participate in Three Investor Conferences During May
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May: H.C. …

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK
LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets …

Global Ureteral Stent Market Set for Robust Growth, Projected to Reach USD 616.8 Million by 2032
Growing Demand and Technological Advancements Drive Expansion in the Ureteral Stent Market: Insights and Projections for 2025 and Beyond NEWARK, DE, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- The global ureteral stent market is experiencing …

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 million Transaction …

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial …

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first …

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval Company to host …

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, …

Assertio Reports First Quarter 2025 Financial Results
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) …

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in …

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results
Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024 Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share Reported preliminary Q1 2025 Adjusted EBITDA of $7.8 million Quarter-end cash …